Bertilimumab: Difference between revisions
Content deleted Content added
Updating {{infobox_drug}} (changes to verified fields - updated 'ChemSpiderID_Ref') per Chem/infobox_drug validation (report errors or bugs) |
Rescuing 4 sources and tagging 0 as dead. #IABot (v1.2.6) |
||
| Line 42: | Line 42: | ||
It was discovered by [[Cambridge Antibody Technology]] using their [[phage display]] technology.<ref>http://jpet.aspetjournals.org/cgi/content/abstract/319/3/1395</ref> Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.<ref>{{cite journal|pmid=15573873 | volume=5 | issue=11 | title=Bertilimumab Cambridge Antibody Technology Group |date=November 2004 | pages=1213–8}}</ref> |
It was discovered by [[Cambridge Antibody Technology]] using their [[phage display]] technology.<ref>http://jpet.aspetjournals.org/cgi/content/abstract/319/3/1395</ref> Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.<ref>{{cite journal|pmid=15573873 | volume=5 | issue=11 | title=Bertilimumab Cambridge Antibody Technology Group |date=November 2004 | pages=1213–8}}</ref> |
||
In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc.<ref>http://www.icotherapeutics.com/site/investor-relations/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/</ref> iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'.<ref>http://www.icotherapeutics.com/site/corporate_overview/overview/</ref> |
In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc.<ref>{{cite web|url=http://www.icotherapeutics.com/site/investor-relations/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/ |title=Archived copy |accessdate=2009-08-01 |deadurl=yes |archiveurl=https://web.archive.org/web/20090501222201/http://www.icotherapeutics.com:80/site/investor-relations/cambridge_antibody_tech_licenses_monoclonal_antibody_treatment_allergy/ |archivedate=2009-05-01 |df= }}</ref> iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'.<ref>{{cite web|url=http://www.icotherapeutics.com/site/corporate_overview/overview/ |title=Archived copy |accessdate=2009-08-01 |deadurl=yes |archiveurl=https://web.archive.org/web/20090728050145/http://www.icotherapeutics.com:80/site/corporate_overview/overview/ |archivedate=2009-07-28 |df= }}</ref> |
||
iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal [[keratoconjunctivitis]].<ref>http://www.icotherapeutics.com/site/pipeline/ico008/</ref> |
iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal [[keratoconjunctivitis]].<ref>{{cite web|url=http://www.icotherapeutics.com/site/pipeline/ico008/ |title=Archived copy |accessdate=2009-08-01 |deadurl=yes |archiveurl=https://web.archive.org/web/20090728131313/http://www.icotherapeutics.com:80/site/pipeline/ico008/ |archivedate=2009-07-28 |df= }}</ref> |
||
In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by [[Lonza Group|Lonza]], in its cGMP facilities in [[Slough]], [[UK]]. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.<ref>http://www.icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_008_phase_ii_clinical_update/</ref> |
In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by [[Lonza Group|Lonza]], in its cGMP facilities in [[Slough]], [[UK]]. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.<ref>{{cite web|url=http://www.icotherapeutics.com/site/investor-relations/ico_therapeutics_provides_ico_008_phase_ii_clinical_update/ |title=Archived copy |accessdate=2009-08-01 |deadurl=yes |archiveurl=https://web.archive.org/web/20090501230056/http://www.icotherapeutics.com:80/site/investor-relations/ico_therapeutics_provides_ico_008_phase_ii_clinical_update/ |archivedate=2009-05-01 |df= }}</ref> |
||
In June 2011, IMMUNE Pharmaceuticals (NASDAQ: IMNP) <ref>http://immunepharmaceuticals.com/</ref> ([[Herzliya, Israel]]) in-licensed Bertilimumab from iCo for non-ophthalmic indications. <ref>http://immunepharmaceuticals.com/index.php?option=com_content&view=article&id=32&Itemid=20</ref> IMMUNE is initiating Phase II clinical trials of Bertilimumab in [[inflammatory bowel disease]] ([[ulcerative colitis]] & [[Crohn's disease]]) in 2015 and 2016. Other indications planned for Bertilimumab development include severe asthma and liver disease (NASH). |
In June 2011, IMMUNE Pharmaceuticals (NASDAQ: IMNP) <ref>http://immunepharmaceuticals.com/</ref> ([[Herzliya, Israel]]) in-licensed Bertilimumab from iCo for non-ophthalmic indications. <ref>http://immunepharmaceuticals.com/index.php?option=com_content&view=article&id=32&Itemid=20</ref> IMMUNE is initiating Phase II clinical trials of Bertilimumab in [[inflammatory bowel disease]] ([[ulcerative colitis]] & [[Crohn's disease]]) in 2015 and 2016. Other indications planned for Bertilimumab development include severe asthma and liver disease (NASH). |
||
Revision as of 19:49, 31 October 2016
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CCL11 (eotaxin-1) |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
  (what is this?) (verify) | |
Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function.
It was discovered by Cambridge Antibody Technology using their phage display technology.[1] Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.[2]
In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc.[3] iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'.[4]
iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis.[5]
In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza, in its cGMP facilities in Slough, UK. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.[6]
In June 2011, IMMUNE Pharmaceuticals (NASDAQ: IMNP) [7] (Herzliya, Israel) in-licensed Bertilimumab from iCo for non-ophthalmic indications. [8] IMMUNE is initiating Phase II clinical trials of Bertilimumab in inflammatory bowel disease (ulcerative colitis & Crohn's disease) in 2015 and 2016. Other indications planned for Bertilimumab development include severe asthma and liver disease (NASH).
References
- ^ http://jpet.aspetjournals.org/cgi/content/abstract/319/3/1395
- ^ "Bertilimumab Cambridge Antibody Technology Group". 5 (11). November 2004: 1213–8. PMID 15573873.
{{cite journal}}: Cite journal requires|journal=(help) - ^ "Archived copy". Archived from the original on 2009-05-01. Retrieved 2009-08-01.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)CS1 maint: archived copy as title (link) - ^ "Archived copy". Archived from the original on 2009-07-28. Retrieved 2009-08-01.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)CS1 maint: archived copy as title (link) - ^ "Archived copy". Archived from the original on 2009-07-28. Retrieved 2009-08-01.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)CS1 maint: archived copy as title (link) - ^ "Archived copy". Archived from the original on 2009-05-01. Retrieved 2009-08-01.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help)CS1 maint: archived copy as title (link) - ^ http://immunepharmaceuticals.com/
- ^ http://immunepharmaceuticals.com/index.php?option=com_content&view=article&id=32&Itemid=20
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |